Publications
2 shownDurable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer
Purpose Nivolumab provides clinical benefit (objective response rate [ORR], 31%; 95% CI, 20.8 to 42.9; disease control rate, 69%; 12-month overall survival [OS], 73%) in previou...
Frequent Co-Authors
Researcher Info
- h-index
- 2
- Publications
- 2
- Citations
- 2,244
- Institution
- The University of Texas MD Anderson Cancer Center
External Links
Identifiers
- ORCID
- 0000-0001-9647-3416
Impact Metrics
h-index
2
h-index: Number of publications with at least h citations each.